BiotechTube

Placebo + AVI-6002

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ebola Hemorrhagic Fever

Conditions

Ebola Hemorrhagic Fever

Trial Timeline

May 1, 2010 → Nov 1, 2011

NCT ID
NCT01353027

About Placebo + AVI-6002

Placebo + AVI-6002 is a phase 1 stage product being developed by United Therapeutics for Ebola Hemorrhagic Fever. The current trial status is completed. This product is registered under clinical trial identifier NCT01353027. Target conditions include Ebola Hemorrhagic Fever.

What happened to similar drugs?

2 of 4 similar drugs in Ebola Hemorrhagic Fever were approved

Approved (2) Terminated (1) Active (1)
✅rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)MerckApproved
✅BioNTech - Pfizer COVID-19 vaccine + 1mL saline solution + rVSV∆G-ZEBOV-GPMerckApproved
🔄V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920MerckPhase 3
❌Ad26.ZEBOV + MVA-BN-FiloBavarian NordicPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01353027Phase 1Completed

Competing Products

20 competing products in Ebola Hemorrhagic Fever

See all competitors
ProductCompanyStageHype Score
Ad26.ZEBOV vaccineJohnson & JohnsonPhase 2
35
rVSVΔG-ZEBOV-GP, V920 + Chikenpox or Varicella vaccine (VARILRIX)MerckPhase 1/2
32
V920 VaccineMerckPhase 1
29
Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)MerckPhase 2
39
rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)MerckApproved
50
V920 (rVSVΔG-ZEBOV-GP) Ebola Virus VaccineMerckPhase 2
35
V920MerckPhase 1
29
V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920MerckPhase 3
40
BioNTech - Pfizer COVID-19 vaccine + 1mL saline solution + rVSV∆G-ZEBOV-GPMerckApproved
50
V920MerckPhase 1
29
GS-5734Gilead SciencesPhase 2
35
REGN3470-3471-3479Regeneron PharmaceuticalsPre-clinical
30
Ervebo + InmazebRegeneron PharmaceuticalsPhase 2
42
AVI-7537United TherapeuticsPhase 1
18
Ad26.ZEBOV + MVA-BN-FiloBavarian NordicPhase 3
29
CMX001Jazz PharmaceuticalsPhase 2
24
BrincidofovirJazz PharmaceuticalsPhase 2
24
cAd3-Marburg + cAd3-EBO-SICON plc.Phase 1
26
Base Dose EBOV GP Vaccine + 2x Base Dose EBOV GP Vaccine + 4x Base Dose EBOV GP Vaccine + 8x Base Dose EBOV GP Vaccine + Placebo + Matrix-M AdjuvantNovavaxPhase 1
23
TKM-100802 for Injection + PlaceboArbutus BiopharmaPhase 1
15